PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 17, 20260 citationsOpen Access

Polyglucosan Inclusion Myopathy as Gastrointestinal Neuromuscular Disease: A Challenge to Diagnosis and Treatment

View Full Paper
GSGiulia SantiBMBenjamin MisselwitzYBYves Borbély

Key Points

  • The aim is to explore the complexities of diagnosing and treating polyglucosan inclusion myopathy as a gastrointestinal neuromuscular disease.
  • Detailed clinical review presented a case of a 54-year-old woman with gastrointestinal symptoms.
  • Diagnostic procedures included endoscopy, manometry, and full thickness bowel biopsy.
  • Treatment involved experimental approaches including fecal transplant and gastric pacing.
  • Biopsy confirmed the presence of polyglucosan bodies, shedding light on the rare disease.
  • Initial treatments showed limited effectiveness, with clinical improvement observed only after gastric pacing and GLP-2 administration.
  • Long-term benefits of experimental treatments like FMT and GLP-2 were not achieved.

Abstract

Background: The polyglucosan inclusion myopathy is a very rare condition that belongs to the gastrointestinal neuromuscular diseases. The accumulation of polyglucosan bodies in the smooth muscles of the gastrointestinal tract can cause intestinal motility disorders up to intestinal failure. The diagnostic and therapeutic pathway of this disease is often tortuous and complex. Case presentation: A 54-year-old caucasian woman presented with a 30-year history of diarrhea, vomiting, malnutrition and intermittent ileus. She had no response to conservative (prucalopride, octreotide, 5-HT agonists) as well as surgical treatment (subtotal colectomy, small bowel resection). Endoscopy revealed a dilated small intestine with duodenal manometry demonstrating gastrointestinal dysmotility. A fecal transplant resulted in temporary improvement only. During laparoscopic placement of a gastric pacemaker full thickness small bowel wall biopsy was performed finally, evidencing the presence of polyglucosan bodies. The gastric pacemaking and the introduction of a Glucagon-like-2 agonist resulted in clinical and nutritional improvement. The latter however, did require discontinuation due to side effects. Conclusion: After thorough routine diagnostic work-up full thickness biopsy with histopathological analysis should be considered in cases of longstanding gastrointestinal neuromuscular disorders of unclear origin. Polyglucosan inclusion myopathy is one of the potential rare etiopathogenesis unmasked by this approach. Treatment of polyglucosan inclusion myopathy is extremely difficult and refractory to common prokinetic therapeutics. Experimental utilization of FMT or off-label use of GLP-2-analogs can be considered but did not deliver long-term benefit in the presented case.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Santi et al. (2024) studied this question.

synapsesocial.com/papers/696b2672d2a12237a9349badhttps://doi.org/10.48620/93478
Ask AI
Helpful
Bookmark
Share
View Full Paper